This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Threshold Pharmaceuticals Reports Second Quarter 2011 Financial And Operational Results

Stocks in this article: THLD

Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), today reported financial results for the second quarter ended June 30, 2011. The net loss for the second quarter and six months ended June 30, 2011 was $7.9 million and $16.3 million, respectively. As of June 30, 2011, Threshold had $31.5 million in cash, cash equivalents and marketable securities, with no debt outstanding.

The net loss for the second quarter of 2011 was $7.9 million compared to $0.3 million for the second quarter of 2010. Included in the net loss, for second quarter of 2011 was non-cash expense of $1.2 million compared to non-cash income of $5.7 million in the second quarter of 2010. The non-cash income (expense) was related to the changes in fair value of the Company’s outstanding warrants and was classified as other income (expense). Research and development expenses were $5.1 million for the second quarter of 2011 compared to $5.0 million for the second quarter of 2010. The increase in research and development expenses primarily reflects an increase in clinical trial expenses related to TH-302. General and administrative expenses were $1.7 million for the second quarter of 2011 versus $1.0 million for the second quarter of 2010. The increase in general and administrative expenses was primarily due to an increase in consulting, facilities and personnel related expenses. Non-cash stock compensation expense for the Company was $0.2 million for the second quarter of 2011 versus $0.2 million for the second quarter of 2010.

For the six months ended June 30, 2011, the net loss was $16.3 million, compared to $6.2 million for the six months ended June 30, 2010. Included in the net loss, for the six months ended June 30, 2011 was non-cash expense of $2.1 million compared to non-cash income of $5.5 million for the six months ended June 30, 2010. The non-cash income (expense) was related to the changes in fair value of the Company’s outstanding warrants and was classified as other income (expense). Research and development expenses were $11.2 million in the first half of 2011 compared to $9.4 million in the first half of 2010, and increased primarily due to clinical trial expenses related to TH-302. General and administrative expenses increased to $3.0 million in the first half of 2011 from $2.3 million in the first half of 2010, primarily due to an increase in consulting, facilities and personnel related expenses. Total non-cash stock compensation expense for the Company was $0.5 million for the first half of 2011 versus $0.3 million for the first half of 2010. This increase was primarily due to the amortization of an increased number of options.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs